ClinicalTrials.gg
RecruitingNCT07798947Updated Oct 19, 2026

A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC

A Phase 2 interventional study of SHR-7787 Injection and SHR-1316 in Limited-stage Small-cell Lung Cancer, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 19, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing adebrelimab in Small Cell Lung Carcinoma — 21 open to participants now, 23 under way, 2 of them phase 3. adebrelimab · Small Cell Lung Carcinoma.

Planned enrollment
4th of 25
120 · median 47
Started
2026
with 4 others
Phase 2
16 of 25
14 open now
Primary completion
2028-12
later than 21 of 22 live
Registered
24th of 25
by date

Among the 25 studies testing adebrelimab in Small Cell Lung Carcinoma, this one is the 4th largest by planned enrollment, is one of 5 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 21 of the 22 other live ones, and was the 24th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

21 of the 25 studies testing adebrelimab in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing adebrelimab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung cancer.

03

Conditions studied

  • Limited-stage Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this clinical study, understand the study procedures, and be able to sign the form (ICF) in writing.
  2. Aged 18 to 75 years (inclusive), of any gender.
  3. or cytologically confirmed unresectable limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemotherapy and radiation therapy.
  4. performance status score of 0 or 1.
  5. Estimated survival time of more than 3 months.
  6. Have adequate bone marrow and organ function.
  7. Female trial participants of must agree to use highly effective from the time of signing the informed consent form until 6 months after the last dose of the drug, and avoid donating eggs.

Exclusion criteria

Exclusion Criteria:

  1. Combined small cell lung cancer or any transformed small cell lung cancer.
  2. History of other within 5 years prior to the first dose of the study drug.
  3. Severe cardiovascular or cerebrovascular diseases.
  4. Bleeding symptoms of significant clinical relevance within 3 months prior to the first dose of the study drug.
  5. Malignant pleural effusion or malignant pericardial effusion.
  6. Severe infection within 4 weeks prior to the initiation of study treatment.
  7. Active tuberculosis infection within 1 year prior to enrollment, identified by medical history or imaging examination.
  8. History of immunodeficiency.
  9. Active, known, or suspected disease, or a history of autoimmune disease.
  10. Prior treatment with (ICIs).
  11. Undergone major organ surgery within 4 weeks prior to the first dose of the study drug.
  12. Any other factors that, in the judgment of the investigator, may affect the study results or force premature termination of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    SHR-7787 (Dose 1) + SHR-1316 group

    Drug: SHR-7787 Injection · Drug: SHR-1316

  • Experimental
    SHR-7787 (Dose 2) + SHR-1316 group

    Drug: SHR-7787 Injection · Drug: SHR-1316

Interventions

  • DrugSHR-7787 Injection

    SHR-7787 injection.

  • SHR-1316 (Adebrelimab) Injection.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    The dose expansion part of Phase 1

    Time frame: Approximately 3 weeks

  2. Incidence and severity of serious adverse events (SAEs)

    The dose expansion part of Phase 1

    Time frame: Approximately 3 weeks

  3. Progression-Free Survival (PFS)

    The dose expansion part of Phase 1

    Time frame: Approximately 16 months

  4. Progression-Free Survival (PFS)

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

Secondary outcomes

  1. Overall Survival (OS)

    The dose expansion part of Phase 1

    Time frame: Approximately 16 months

  2. Objective Response Rate (ORR)

    The dose expansion part of Phase 1

    Time frame: Approximately 16 months

  3. Duration of Response (DoR)

    The dose expansion part of Phase 1

    Time frame: Approximately 16 months

  4. Anti-Drug Antibody (ADA) of SHR-7787

    The dose expansion part of Phase 1

    Time frame: Approximately 16 months

  5. Disease Control Rate (DCR)

    The dose expansion part of Phase 1

    Time frame: Approximately 16 months

  6. Disease Control Rate (DCR)

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

  7. Overall Survival (OS)

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

  8. Objective Response Rate (ORR)

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

  9. Duration of Response (DoR)

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

  10. Anti-Drug Antibody (ADA) of SHR-7787

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

  11. Incidence and severity of adverse events (AEs)

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

  12. Incidence and severity of serious adverse events (SAEs)

    The efficacy expansion part of Phase 2

    Time frame: Approximately 16 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's planned 26 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Sep 2, 2026
StartActual
Oct 7, 2026was Sep 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
Cancer Hospital of Shandong First Medical University is now Recruiting
Oct 19, 2026
Start date
Sep 2026→Oct 7, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Recruiting
    Cancer Hospital of Shandong First Medical University is now Recruiting
    Start date Sep 2026→Oct 7, 2026 (now actual)
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07798947
Responsible party
Sponsor
First posted
Sep 2, 2026
Start date
Oct 7, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Xiaoxia Lu
Contact
xiaoxia.lu@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adebrelimab

Start the discussion